prikaz prve stranice dokumenta Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach
  Preuzmi
PDF 632.8 KB
Znanstveni rad - Izvorni znanstveni rad
Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach
European Journal of Clinical Microbiology and Infectious Diseases, 40 (2021), 2; 261-268. https://doi.org/10.1007/s10096-020-04019-y
Rode, Oktavija Đaković; Kurolt, Ivan-Christian; Puljiz, Ivan; Čivljak, Rok; Balent, Nataša Cetinić; Laškaj, Renata; Tiljak, Mirjana Kujundžić; Mikulić, Radojka; Markotić, Alemka

Povezani objekti
COVID-19 | Virtualna zbirka
Citirajte ovaj rad

Rode, O. Đ., Kurolt, I. C., Puljiz, I., Čivljak, R., Balent, N. C., Laškaj, R. ... Markotić, A. (2021). Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach. European Journal of Clinical Microbiology and Infectious Diseases, 40. (2), 261-268. doi: 10.1007/s10096-020-04019-y

Rode, Oktavija Đaković, et al. "Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach." European Journal of Clinical Microbiology and Infectious Diseases, vol. 40, br. 2, 2021, str. 261-268. https://doi.org/10.1007/s10096-020-04019-y

Rode, Oktavija Đaković, Ivan Christian Kurolt, Ivan Puljiz, Rok Čivljak, Nataša Cetinić Balent, Renata Laškaj, Mirjana Kujundžić Tiljak, Radojka Mikulić i Alemka Markotić. "Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach." European Journal of Clinical Microbiology and Infectious Diseases 40, br. 2 (2021): 261-268. https://doi.org/10.1007/s10096-020-04019-y

Rode, O. Đ., et al. (2021) 'Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach', European Journal of Clinical Microbiology and Infectious Diseases, 40(2), str. 261-268. doi: 10.1007/s10096-020-04019-y

Rode OĐ, Kurolt IC, Puljiz I, Čivljak R, Balent NC, Laškaj R, i sur.. Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach. European Journal of Clinical Microbiology and Infectious Diseases [Internet]. 02.2021. [pristupljeno 19.04.2024.];40(2):261-268. doi: 10.1007/s10096-020-04019-y

O. Đ. Rode, et al., "Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach", European Journal of Clinical Microbiology and Infectious Diseases, vol. 40, br. 2, str. 261-268, Veljača 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:576675. [Citirano: 19.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:576675
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach
AutorOktavija Đaković Rode
AutorIvan-Christian Kurolt
AutorIvan Puljiz
AutorRok Čivljak
AutorNataša Cetinić Balent
AutorRenata Laškaj
AutorMirjana Kujundžić Tiljak
AutorRadojka Mikulić
AutorAlemka Markotić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za zarazne bolesti)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Infektologija
Sažetak (engleski)
According to anti-SARS-CoV-2 seroresponse in patients with COVID-19 from Croatia, we emphasised the issue of different serological tests and need for combining diagnostic methods for COVID-19 diagnosis. Anti-SARS-CoV-2 IgA and IgG ELISA and IgM/IgG immunochromatographic assay (ICA) were used for testing 60 sera from 21 patients (6 with severe, 10 moderate, and 5 with mild disease). The main clinical, demographic, and haemato-biochemical data were analysed. The most common symptoms were cough (95.2%), fever (90.5%), and fatigue and shortness of breath (42.9%). Pulmonary opacities showed 76.2% of patients. Within the first 7 days of illness, seropositivity for ELISA IgA and IgG was 42.9% and 7.1%, and for ICA IgM and IgG 25% and 10.7%, respectively. From day 8 after onset, ELISA IgA and IgG seropositivity was 90.6% and 68.8%, and for ICA IgM and IgG 84.4% and 75%, respectively. In general, sensitivity for ELISA IgA and IgG was 68.3% and 40%, and for ICA IgM and IgG 56.7% and 45.0%, respectively. The anti-SARS-CoV-2 antibody distributions by each method were statistically different (ICA IgM vs. IgG, p = 0.016; ELISA IgG vs. IgA, p < 0.001). Antibody response in COVID-19 varies and depends on the time the serum is taken, on the severity of disease, and on the type of test used. IgM and IgA antibodies as early-stage disease markers are comparable, although they cannot replace each other. Simultaneous IgM/IgG/IgA anti-SARS-CoV-2 antibody testing followed by the confirmation of positive findings with another test in a two-tier testing is recommended.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaEuropean Journal of Clinical Microbiology and Infectious Diseases
Brojčani podacivol. 40, br. 2, str. 261-268
p-ISSN0934-9723
e-ISSN1435-4373
DOIhttps://doi.org/10.1007/s10096-020-04019-y
URN:NBNurn:nbn:hr:184:576675
Datum objave publikacije2021-02
URL dokumentahttps://pubmed.ncbi.nlm.nih.gov/32886230/
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2020-10-04 18:56:09